4D Molecular Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.13M, a 30.81% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $860.00K, a 21.64% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $707.00K, a 7.45% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $658.00K, a 39.70% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.25M, a 0.40% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.26M, a 6.79% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.18M, a 43.13% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $823.00K, a 90.07% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.25M 10-K · filed 2026-03-18 | |
| 2025-06-30 | $860.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $1.26M 10-K · filed 2026-03-18 | |
| 2024-06-30 | $707.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $1.18M 10-K · filed 2025-02-28 | |
| 2023-06-30 | $658.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $823.00K 10-K · filed 2024-02-29 | |
| 2022-06-30 | $471.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $433.00K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |